0000899243-21-004749.txt : 20210203 0000899243-21-004749.hdr.sgml : 20210203 20210203184212 ACCESSION NUMBER: 0000899243-21-004749 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210201 FILED AS OF DATE: 20210203 DATE AS OF CHANGE: 20210203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Peters Richard CENTRAL INDEX KEY: 0001697628 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37695 FILM NUMBER: 21587939 MAIL ADDRESS: STREET 1: MERRIMACK PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: YUMANITY THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001445283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 GUEST STREET STREET 2: SUITE 4410 CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-409-5300 MAIL ADDRESS: STREET 1: 40 GUEST STREET STREET 2: SUITE 4410 CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140813 FORMER COMPANY: FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC DATE OF NAME CHANGE: 20080916 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-01 0 0001445283 YUMANITY THERAPEUTICS, INC. YMTX 0001697628 Peters Richard C/O YUMANITY THERAPEUTICS, INC 40 GUEST STREET, SUITE 4410 BOSTON MA 02135 1 1 0 0 President & CEO Common Stock 2021-02-01 4 A 0 60943 0.00 A 60943 D Stock Option (Right to Buy) 17.89 2021-02-01 4 A 0 120000 0.00 A 2031-01-31 Common Stock 120000 120000 D Stock Option (Right to Buy) 17.89 2021-02-01 4 A 0 60944 0.00 A 2031-01-31 Common Stock 60944 60944 D The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in four equal annual installments over four years following July 1, 2020. This option shall vest and become exercisable in 48 equal monthly installments over four years following the Grant Date. This option shall vest and become exercisable in 48 equal monthly installments over four years following July 1, 2020. /s/ Marie Epstein, Attorney-in-Fact 2021-02-03